• n-Dodecyl-β-D-maltoside for WecA Assays

  2026-08-17

  Discover how n-Dodecyl-β-D-maltoside and DDM can be optimized as assay variables rather than treated as passive extraction reagents. This guide connects micelle chemistry, WecA purification, kinetic readouts, surface adsorption, and protein–lipid interaction studies.

• PS Nanoplastics Rewire Vascular Lipid Signaling

  2026-08-16

  A 2026 study links prenatal and lactational exposure to polystyrene nanoplastics with lipid accumulation in vascular smooth muscle cells of male offspring through the MAPK/ERK/UHRF1 axis. Pharmacological ERK-pathway inhibition and UHRF1 knockdown provide complementary evidence that this signaling cascade contributes to early vascular lipid dysregulation.

• Tigecycline in the Resistance-Transfer Era

  2026-08-15

  Tigecycline offers translational researchers a mechanistically distinct glycylcycline antibiotic for studying resistant bacterial phenotypes. By connecting 30S ribosomal inhibition with the plasmid-mediated transmission dynamics reported in carbapenem-resistant Enterobacter cloacae, this article outlines a practical framework for in vitro, in vivo, and clinical research decisions.

• Propranolol and Essential Tremor: TMS Mechanisms

  2026-08-14

  A prospective observational study used transcranial magnetic stimulation and accelerometry to distinguish how primidone and propranolol reduce essential tremor. The findings associate propranolol with reduced corticospinal excitability and increased short afferent inhibition, supporting a central noradrenergic influence on GABAergic motor-circuit regulation alongside its established peripheral effects.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-08-14

  Pitavastatin (NK-104, SKU B1124) is a defined HMG-CoA reductase inhibitor for controlled cell-based and biochemical studies of cholesterol biosynthesis. This guide supports in vitro assay planning and quality control, but the available dossier does not validate clinical use, animal dosing, or a directly matched paper-based protocol.

• Indole-3-pyruvic acid: Applied Workflow Guide

  2026-08-13

  Learn how Indole-3-pyruvic acid supports plant auxin studies, PBMC immune assays, and preclinical rheumatoid arthritis research. This workflow-focused guide covers dosing logic, AhR mechanism checks, storage, and troubleshooting for more reproducible IPA experiments.

• Thioguanine Workflows for Antiviral and Cancer Assays

  2026-08-13

  Thioguanine, also called 6-thioguanine, supports mechanism-led antiviral, cancer, and epigenetic assay design. This guide translates EV71 findings into practical workflows while showing how solubility, controls, and orthogonal readouts improve reproducibility.

• AO/PI Double Staining Kit for Organoid Decisions

  2026-08-12

  Discover how the AO/PI Double Staining Kit can turn organoid viability measurements into more defensible cell-state decisions. This guide connects Acridine Orange Propidium Iodide staining with glioma microenvironment models, sampling strategy, and orthogonal validation.

• G007-LK: A Mechanism-First Tankyrase Guide

  2026-08-12

  G007-LK is a selective tankyrase 1/2 inhibitor for resolving how PARylation controls AXIN stability, β-catenin turnover, and context-dependent tumor signaling. This mechanism-first guide connects assay design with colorectal and hepatocellular carcinoma evidence.

• n-Dodecyl-β-D-maltoside for Integrin Cryo-EM

  2026-08-11

  Learn how DDM can support full-length αvβ3 integrin solubilization, purification, conformational screening, and cryo-EM sample preparation. The workflow emphasizes matched detergent conditions, ligand-state preservation, and practical troubleshooting rather than treating DDM as a one-size-fits-all solution.

• BIRB 796: Applied p38α MAPK Workflows

  2026-08-11

  BIRB 796 (Doramapimod) combines selective allosteric p38α MAPK inhibition with a practical route to dissect inflammatory signaling, cytokine production, and apoptosis. This workflow-focused guide covers dosing design, phospho-signaling assays, dephosphorylation experiments, and troubleshooting for cell-based and translational studies.

• Meropenem Workflows for Resistant Bacterial Models

  2026-08-10

  Build reproducible MIC, time-kill, resistance, and translational infection workflows around Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem. The article connects exposure-based assay design with Gram-negative bacterial infection models, nanoparticle research, and troubleshooting strategies for carbapenem-resistant bacterial infections.

• CX-4945 (Silmitasertib): CK2 and Cancer Stemness

  2026-08-09

  CX-4945, also known as Silmitasertib, offers a translational route from CK2 biology to cancer stemness, therapy resistance, apoptosis, and cell-cycle control. This article interprets evidence linking CK2-dependent ECE-1c stability to aggressive NSCLC phenotypes and provides a practical framework for validating CK2-driven mechanisms in cancer models.

• Meropenem in Reliable Cell and Infection Assays

  2026-08-08

  This scenario-based guide explains how Meropenem (SKU A5124) can reduce bacterial confounding in viability, proliferation, cytotoxicity, and infection-model workflows. It covers mechanism, stock preparation, concentration design, interpretation, and practical supplier selection using product specifications and relevant β-lactam literature.

• Meropenem Assay Design for Resistance Research

  2026-08-07

  Meropenem is a β-lactam antibiotic carbapenem with unusually broad activity for mechanistic infection studies. This guide presents a translational assay framework linking PBP inhibition, exposure above MIC, resistance phenotyping, and nanoparticle-based septicemia research.

15745 records 1/1050 page Next 12345 下5页 Last page